Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial
Hejia Wang(Bloomberg (United States)), Neeha Zaidi(Johns Hopkins University), Michael J. Pishvaian(The University of Texas MD Anderson Cancer Center), Amanda L. Huff(Johns Hopkins University), Marina Baretti(Sidney Kimmel Comprehensive Cancer Center), Christopher J. Thoburn(Johns Hopkins University), Daniel A. Laheru(Bloomberg (United States)), Elizabeth M. Jaffee(Bloomberg (United States)), Maureen Berg(Johns Hopkins University), Mark Yarchoan(Sidney Kimmel Comprehensive Cancer Center), Katherine M. Bever(Sidney Kimmel Comprehensive Cancer Center), Hao Wang(The University of Sydney), S. Daniel Haldar(Bloomberg (United States)), Benjamin Barrett(Bloomberg (United States)), J H Lu(Johns Hopkins University), Eric S. Christenson(Bloomberg (United States)), Valerie Lee(Johns Hopkins University), Nilofer S. Azad(Johns Hopkins University), Robert A. Anders(Bloomberg (United States)), Julie M. Nauroth(Johns Hopkins University), Amy Thomas(Johns Hopkins University), Dung T. Le(Johns Hopkins University), Thatcher R. Heumann(Bloomberg (United States)), Jennifer N. Durham(Sidney Kimmel Comprehensive Cancer Center)
Cited by 1
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k